Systematic evaluation of immune regulation and modulation

• Type of Material: Article
• Authors: David F. Stroncek, National Institutes of Health; Lisa H. Butterfield, University of Pittsburgh; Michael A. Cannarile, Roche Innovation Center Munich; Madhav Dhodapkar, Emory University; Tim F. Greten, National Cancer Institute; Jean Charles Grivel, Sidra Medical and Research Center; David R. Kaufman, Merck Research Laboratories; Heidi H. Kong, National Cancer Institute; Firouzeh Korangy, National Cancer Institute; Peter P. Lee, City Hope National Medical Center; Francesco Marincola, Sidra Medical and Research Center; Sergio Rutella, Nottingham Trent University; Janet C. Siebert, CytoAnalytics; Giorgio Trinchieri, National Cancer Institute; Barbara Seliger, Martin Luther University Halle Wittenberg
• Language: English
• Date: 2017-03-21
• Publisher: BMJ Publishing Group: Open Access
• Publication Version: Final Published Version
• Copyright Statement: © 2017 The Author(s).
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s40425-017-0223-8
• Title of Journal or Parent Work: Journal for ImmunoTherapy of Cancer
• ISSN: 2051-1426
• Volume: 5
• Issue: 1
• Start Page: 21
• End Page: 21
• Keywords: Science & Technology; SAMPLE COLLECTION; Immunology; ADOPTIVE TRANSFER; CD8(+) T-CELLS; CTLA-4 BLOCKADE; TUMOR-INFILTRATING LYMPHOCYTES; High-throughput; DNA MISMATCH REPAIR; Life Sciences & Biomedicine; Oncology; SUPPRESSOR-CELLS; METASTATIC MELANOMA PATIENTS; Immune regulation; PD-1 BLOCKADE; Systematic monitoring; MASS CYTOMETRY; Immune biomarkers
• Research Categories: Health Sciences, Oncology; Health Sciences, Immunology

Abstract

Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in the field. Moreover, the identification and assessment of both predictive and prognostic biomarkers has become a key component to advancing these therapies. Thus, it is critical to develop systematic approaches to monitor the immune response and to interpret the data obtained from these assays. In order to address these issues and make recommendations to the field, the Society for Immunotherapy of Cancer reconvened the Immune Biomarkers Task Force. As a part of this Task Force, Working Group 3 (WG3) consisting of multidisciplinary experts from industry, academia, and government focused on the systematic assessment of immune regulation and modulation. In this review, the tumor microenvironment, microbiome, bone marrow, and adoptively transferred T cells will be used as examples to discuss the type and timing of sample collection. In addition, potential types of measurements, assays, and analyses will be discussed for each sample. Specifically, these recommendations will focus on the unique collection and assay requirements for the analysis of various samples as well as the high-throughput assays to evaluate potential biomarkers.